ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
4:00 PM ET on Jan 30, 2015
Delayed at least 20 minutes.
Provided by eSignal.
Jan 6, 2015
ChemoCentryx to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Dec 12, 2014
ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
Dec 11, 2014
ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II Results in Patients With Diabetic Nephropathy With CCX140, an Orally Administered CCR2 Inhibitor
^ Return to Top